Stock Events

Stock Events

Incyte 

$126.75
194
-$1.25-0.98% 20:00 Today
+$0.00+0%21:04After hours

Statistics

Day High
128.05
Day Low
126.04
52W High
132.6
52W Low
81.09
Volume
1,000,072
Avg. Volume
1,811,582
Mkt Cap
25.69B
P/E Ratio
16.48
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-2.83
-0.86
1.12
3.09
Expected EPS
-2.828265
Actual EPS
N/A

Financials

25.03%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
5.14BRevenue
1.29BNet Income

Analyst Ratings

122.94Average Price Target
The highest estimate is 155.00.
From 17 ratings within the last 6 months. This is not an investment recommendation.
Buy
47%
Hold
53%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow INCY. It's not an investment recommendation.
Microsoft
60
MSFT
Amazon
57
AMZN
NVIDIA
57
NVDA
Apple
51
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Amgen competes with Incyte in the biopharmaceutical sector, focusing on innovative therapeutics in areas overlapping with Incyte's interests, such as oncology and inflammation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences operates in similar therapeutic areas as Incyte, including oncology and antiviral drugs, making them direct competitors in the market for cancer and other treatments.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Incyte in the development of cancer treatments and immunotherapies, areas where Incyte is also heavily invested.
Merck
MRK
Mkt Cap366B
Merck is a leading pharmaceutical company that competes with Incyte in the oncology sector, particularly in the development and marketing of cancer treatments.
Novartis
NVS
Mkt Cap292.35B
Novartis competes with Incyte in multiple areas, including oncology and autoimmune diseases, with a broad portfolio that overlaps with Incyte's research and development focus.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical giant that competes with Incyte in the development of drugs for various diseases, including cancer, which is a key focus area for Incyte.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG competes with Incyte in the oncology and hematology fields, with a strong focus on developing innovative cancer treatments.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie competes with Incyte in the area of immunology and oncology, particularly in the development of treatments for cancers and autoimmune diseases.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company competes with Incyte in the pharmaceutical sector, focusing on areas such as oncology, which is a significant part of Incyte's business.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is a competitor in the biopharmaceutical field, focusing on innovative treatments in areas like oncology and inflammatory diseases, directly competing with Incyte's research and product offerings.

About

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Show more...
CEO
William J. Meury
Employees
2844
Country
United States
ISIN
US45337C1027
WKN
000896133

Listings

XETRA
DE
ICY.XETRA
STU
DE
ICY.STU
SA
BR
I1NC34.SA
LSE
GB
0J9P.LSE

0 Comments

Share your thoughts

FAQ

What is Incyte stock price today?▼
The current price of INCY is $126.75 USD — it has decreased by -0.98% in the past 24 hours. Watch Incyte stock price performance more closely on the chart.
What is Incyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Incyte stocks are traded under the ticker INCY.
Is Incyte stock price growing?▼
INCY stock has risen by +1.91% compared to the previous week, the month change is a +5.1% rise, over the last year Incyte has showed a +48.35% increase.
What is Incyte market cap?▼
Today Incyte has the market capitalization of 25.69B
When is the next Incyte earnings date?▼
Incyte is going to release the next earnings report on November 03, 2026.
What were Incyte earnings last quarter?▼
INCY earnings for the last quarter are 3.09 USD per share, whereas the estimation was 2.2 USD resulting in a +40.72% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Incyte revenue for the last year?▼
Incyte revenue for the last year amounts to 5.14B USD.
What is Incyte net income for the last year?▼
INCY net income for the last year is 1.29B USD.
How many employees does Incyte have?▼
As of September 04, 2026, the company has 2,844 employees.
In which sector is Incyte located?▼
Incyte operates in the Health & Wellness sector.
When did Incyte complete a stock split?▼
The last stock split for Incyte was on September 01, 2000 with a ratio of 2:1.
Where is Incyte headquartered?▼
Incyte is headquartered in WILMINGTON, United States.